Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Oncogenic BRAFV600E governs regulatory T cell recruitment during melanoma tumorigenesis.

Shabaneh TB, Molodtsov A, Steinberg SM, Zhang P, Torres GM, Mohamed GA, Boni A, Curiel TJ, Angeles CV, Turk MJ.

Cancer Res. 2018 Jul 19. pii: canres.0365.2018. doi: 10.1158/0008-5472.CAN-18-0365. [Epub ahead of print]

PMID:
30026331
2.

Author Correction: Attenuation of RNA polymerase II pausing mitigates BRCA1-associated R-loop accumulation and tumorigenesis.

Zhang X, Chiang HC, Wang Y, Zhang C, Smith S, Zhao X, Nair SJ, Michalek J, Jatoi I, Lautner M, Oliver B, Wang H, Petit A, Soler T, Brunet J, Mateo F, Angel Pujana M, Poggi E, Chaldekas K, Isaacs C, Peshkin BN, Ochoa O, Chedin F, Theoharis C, Sun LZ, Curiel TJ, Elledge R, Jin VX, Hu Y, Li R.

Nat Commun. 2018 Mar 30;9:16211. doi: 10.1038/ncomms16211.

3.

A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects.

Kraig E, Linehan LA, Liang H, Romo TQ, Liu Q, Wu Y, Benavides AD, Curiel TJ, Javors MA, Musi N, Chiodo L, Koek W, Gelfond JAL, Kellogg DL Jr.

Exp Gerontol. 2018 May;105:53-69. doi: 10.1016/j.exger.2017.12.026. Epub 2018 Feb 3.

PMID:
29408453
4.

Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model.

Padrón Á, Hurez V, Gupta HB, Clark CA, Pandeswara SL, Yuan B, Svatek RS, Turk MJ, Drerup JM, Li R, Curiel TJ.

Exp Gerontol. 2018 May;105:146-154. doi: 10.1016/j.exger.2017.12.025. Epub 2018 Jan 8.

PMID:
29326088
5.

Tumor-extrinsic discoidin domain receptor 1 promotes mammary tumor growth by regulating adipose stromal interleukin 6 production in mice.

Sun X, Gupta K, Wu B, Zhang D, Yuan B, Zhang X, Chiang HC, Zhang C, Curiel TJ, Bendeck MP, Hursting S, Hu Y, Li R.

J Biol Chem. 2018 Feb 23;293(8):2841-2849. doi: 10.1074/jbc.RA117.000672. Epub 2018 Jan 3.

PMID:
29298894
6.

Considerations for successful cancer immunotherapy in aged hosts.

Hurez V, Padrón Á, Svatek RS, Curiel TJ.

Exp Gerontol. 2018 Jul 1;107:27-36. doi: 10.1016/j.exger.2017.10.002. Epub 2017 Oct 4. Review.

PMID:
28987644
7.

Attenuation of RNA polymerase II pausing mitigates BRCA1-associated R-loop accumulation and tumorigenesis.

Zhang X, Chiang HC, Wang Y, Zhang C, Smith S, Zhao X, Nair SJ, Michalek J, Jatoi I, Lautner M, Oliver B, Wang H, Petit A, Soler T, Brunet J, Mateo F, Angel Pujana M, Poggi E, Chaldekas K, Isaacs C, Peshkin BN, Ochoa O, Chedin F, Theoharis C, Sun LZ, Curiel TJ, Elledge R, Jin VX, Hu Y, Li R.

Nat Commun. 2017 Jun 26;8:15908. doi: 10.1038/ncomms15908. Erratum in: Nat Commun. 2018 Mar 30;9:16211.

8.

Tumor cell-intrinsic CD274/PD-L1: A novel metabolic balancing act with clinical potential.

Clark CA, Gupta HB, Curiel TJ.

Autophagy. 2017 May 4;13(5):987-988. doi: 10.1080/15548627.2017.1280223. Epub 2017 Apr 3.

9.

Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors.

Steinberg SM, Shabaneh TB, Zhang P, Martyanov V, Li Z, Malik BT, Wood TA, Boni A, Molodtsov A, Angeles CV, Curiel TJ, Whitfield ML, Turk MJ.

Cancer Res. 2017 Apr 1;77(7):1599-1610. doi: 10.1158/0008-5472.CAN-16-1755. Epub 2017 Feb 15.

10.

Biphasic Rapamycin Effects in Lymphoma and Carcinoma Treatment.

Liu Y, Pandeswara S, Dao V, Padrón Á, Drerup JM, Lao S, Liu A, Hurez V, Curiel TJ.

Cancer Res. 2017 Jan 15;77(2):520-531. doi: 10.1158/0008-5472.CAN-16-1140. Epub 2016 Oct 13.

11.

Tumor Cell-Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells.

Svoronos N, Perales-Puchalt A, Allegrezza MJ, Rutkowski MR, Payne KK, Tesone AJ, Nguyen JM, Curiel TJ, Cadungog MG, Singhal S, Eruslanov EB, Zhang P, Tchou J, Zhang R, Conejo-Garcia JR.

Cancer Discov. 2017 Jan;7(1):72-85. doi: 10.1158/2159-8290.CD-16-0502. Epub 2016 Sep 30.

12.

Considerations for successful cancer immunotherapy in aged hosts.

Hurez V, Padrón ÁS, Svatek RS, Curiel TJ.

Clin Exp Immunol. 2017 Jan;187(1):53-63. doi: 10.1111/cei.12875. Epub 2016 Nov 7. Review.

13.

Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma.

Clark CA, Gupta HB, Sareddy G, Pandeswara S, Lao S, Yuan B, Drerup JM, Padron A, Conejo-Garcia J, Murthy K, Liu Y, Turk MJ, Thedieck K, Hurez V, Li R, Vadlamudi R, Curiel TJ.

Cancer Res. 2016 Dec 1;76(23):6964-6974. Epub 2016 Sep 26. Erratum in: Cancer Res. 2017 May 15;77(10 ):2770.

14.

Immune-Stimulatory Effects of Rapamycin Are Mediated by Stimulation of Antitumor γδ T Cells.

Dao V, Liu Y, Pandeswara S, Svatek RS, Gelfond JA, Liu A, Hurez V, Curiel TJ.

Cancer Res. 2016 Oct 15;76(20):5970-5982. Epub 2016 Aug 28.

15.

Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target.

Perales-Puchalt A, Svoronos N, Rutkowski MR, Allegrezza MJ, Tesone AJ, Payne KK, Wickramasinghe J, Nguyen JM, O'Brien SW, Gumireddy K, Huang Q, Cadungog MG, Connolly DC, Tchou J, Curiel TJ, Conejo-Garcia JR.

Clin Cancer Res. 2017 Jan 15;23(2):441-453. doi: 10.1158/1078-0432.CCR-16-0492. Epub 2016 Jul 19.

16.

Tyrosine phosphorylation regulates ERβ ubiquitination, protein turnover, and inhibition of breast cancer.

Yuan B, Cheng L, Gupta K, Chiang HC, Gupta HB, Sareddy GR, Wang D, Lathrop K, Elledge R, Wang P, McHardy S, Vadlamudi R, Curiel TJ, Hu Y, Ye Q, Li R.

Oncotarget. 2016 Jul 5;7(27):42585-42597. doi: 10.18632/oncotarget.10018.

17.

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.

Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, O'Donnell PH, Drakaki A, Tan W, Kurland JF, Rebelatto MC, Jin X, Blake-Haskins JA, Gupta A, Segal NH.

J Clin Oncol. 2016 Sep 10;34(26):3119-25. doi: 10.1200/JCO.2016.67.9761. Epub 2016 Jun 6.

18.

Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer.

Gupta HB, Clark CA, Yuan B, Sareddy G, Pandeswara S, Padron AS, Hurez V, Conejo-Garcia J, Vadlamudi R, Li R, Curiel TJ.

Signal Transduct Target Ther. 2016;1. pii: 16030. doi: 10.1038/sigtrans.2016.30. Epub 2016 Dec 23.

19.

Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune-deficient mice.

Hurez V, Dao V, Liu A, Pandeswara S, Gelfond J, Sun L, Bergman M, Orihuela CJ, Galvan V, Padrón Á, Drerup J, Liu Y, Hasty P, Sharp ZD, Curiel TJ.

Aging Cell. 2015 Dec;14(6):945-56. doi: 10.1111/acel.12380. Epub 2015 Aug 28.

20.

Interventions to Slow Aging in Humans: Are We Ready?

Longo VD, Antebi A, Bartke A, Barzilai N, Brown-Borg HM, Caruso C, Curiel TJ, de Cabo R, Franceschi C, Gems D, Ingram DK, Johnson TE, Kennedy BK, Kenyon C, Klein S, Kopchick JJ, Lepperdinger G, Madeo F, Mirisola MG, Mitchell JR, Passarino G, Rudolph KL, Sedivy JM, Shadel GS, Sinclair DA, Spindler SR, Suh Y, Vijg J, Vinciguerra M, Fontana L.

Aging Cell. 2015 Aug;14(4):497-510. doi: 10.1111/acel.12338. Epub 2015 Apr 22. Review.

21.

Prevention of carcinogen and inflammation-induced dermal cancer by oral rapamycin includes reducing genetic damage.

Dao V, Pandeswara S, Liu Y, Hurez V, Dodds S, Callaway D, Liu A, Hasty P, Sharp ZD, Curiel TJ.

Cancer Prev Res (Phila). 2015 May;8(5):400-9. doi: 10.1158/1940-6207.CAPR-14-0313-T. Epub 2015 Mar 3.

22.

Immunotherapy for ovarian cancer.

Drerup JM, Liu Y, Padron AS, Murthy K, Hurez V, Zhang B, Curiel TJ.

Curr Treat Options Oncol. 2015 Jan;16(1):317. doi: 10.1007/s11864-014-0317-1. Review.

23.

Host miR155 promotes tumor growth through a myeloid-derived suppressor cell-dependent mechanism.

Chen S, Wang L, Fan J, Ye C, Dominguez D, Zhang Y, Curiel TJ, Fang D, Kuzel TM, Zhang B.

Cancer Res. 2015 Feb 1;75(3):519-31. doi: 10.1158/0008-5472.CAN-14-2331. Epub 2014 Dec 10.

24.

Sequential intravesical mitomycin plus Bacillus Calmette-Guérin for non-muscle-invasive urothelial bladder carcinoma: translational and phase I clinical trial.

Svatek RS, Zhao XR, Morales EE, Jha MK, Tseng TY, Hugen CM, Hurez V, Hernandez J, Curiel TJ.

Clin Cancer Res. 2015 Jan 15;21(2):303-11. doi: 10.1158/1078-0432.CCR-14-1781. Epub 2014 Nov 25.

25.

Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors.

Mahalingam D, Mita M, Sarantopoulos J, Wood L, Amaravadi RK, Davis LE, Mita AC, Curiel TJ, Espitia CM, Nawrocki ST, Giles FJ, Carew JS.

Autophagy. 2014 Aug;10(8):1403-14. doi: 10.4161/auto.29231. Epub 2014 May 20.

26.

A phosphotyrosine switch determines the antitumor activity of ERβ.

Yuan B, Cheng L, Chiang HC, Xu X, Han Y, Su H, Wang L, Zhang B, Lin J, Li X, Xie X, Wang T, Tekmal RR, Curiel TJ, Yuan ZM, Elledge R, Hu Y, Ye Q, Li R.

J Clin Invest. 2014 Aug;124(8):3378-90. doi: 10.1172/JCI74085. Epub 2014 Jun 24.

27.

Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis.

Messer JC, Shariat SF, Dinney CP, Novara G, Fradet Y, Kassouf W, Karakiewicz PI, Fritsche HM, Izawa JI, Lotan Y, Skinner EC, Tilki D, Ficarra V, Volkmer BG, Isbarn H, Wei C, Lerner SP, Curiel TJ, Kamat AM, Svatek RS.

Urology. 2014 Apr;83(4):863-7. doi: 10.1016/j.urology.2013.10.060. Epub 2014 Jan 31.

PMID:
24485993
28.

eRapa restores a normal life span in a FAP mouse model.

Hasty P, Livi CB, Dodds SG, Jones D, Strong R, Javors M, Fischer KE, Sloane L, Murthy K, Hubbard G, Sun L, Hurez V, Curiel TJ, Sharp ZD.

Cancer Prev Res (Phila). 2014 Jan;7(1):169-78. doi: 10.1158/1940-6207.CAPR-13-0299. Epub 2013 Nov 26.

29.

TgMAPK1 is a Toxoplasma gondii MAP kinase that hijacks host MKK3 signals to regulate virulence and interferon-γ-mediated nitric oxide production.

Brumlik MJ, Pandeswara S, Ludwig SM, Jeansonne DP, Lacey MR, Murthy K, Daniel BJ, Wang RF, Thibodeaux SR, Church KM, Hurez V, Kious MJ, Zhang B, Alagbala A, Xia X, Curiel TJ.

Exp Parasitol. 2013 Jul;134(3):389-99. doi: 10.1016/j.exppara.2013.03.016. Epub 2013 Mar 27.

30.

Graft-versus-host disease is enhanced by selective CD73 blockade in mice.

Wang L, Fan J, Chen S, Zhang Y, Curiel TJ, Zhang B.

PLoS One. 2013;8(3):e58397. doi: 10.1371/journal.pone.0058397. Epub 2013 Mar 8.

31.

Chronic mechanistic target of rapamycin inhibition: preventing cancer to delay aging, or vice versa?.

Sharp ZD, Curiel TJ, Livi CB.

Interdiscip Top Gerontol. 2013;38:1-16. doi: 10.1159/000343625. Epub 2013 Jan 17. Review.

PMID:
23503511
32.

Optimization of immunotherapy in elderly cancer patients.

Tomihara K, Curiel TJ, Zhang B.

Crit Rev Oncog. 2013;18(6):573-83. Review.

33.

mTORC1 and p53: clash of the gods?

Hasty P, Sharp ZD, Curiel TJ, Campisi J.

Cell Cycle. 2013 Jan 1;12(1):20-5.

34.

Antiestrogenic activity of flavonoid phytochemicals mediated via the c-Jun N-terminal protein kinase pathway. Cell-type specific regulation of estrogen receptor alpha.

Collins-Burow BM, Antoon JW, Frigo DE, Elliott S, Weldon CB, Boue SM, Beckman BS, Curiel TJ, Alam J, McLachlan JA, Burow ME.

J Steroid Biochem Mol Biol. 2012 Oct;132(1-2):186-93. doi: 10.1016/j.jsbmb.2012.05.004. Epub 2012 May 24.

35.

Mitigating age-related immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice.

Hurez V, Daniel BJ, Sun L, Liu AJ, Ludwig SM, Kious MJ, Thibodeaux SR, Pandeswara S, Murthy K, Livi CB, Wall S, Brumlik MJ, Shin T, Zhang B, Curiel TJ.

Cancer Res. 2012 Apr 15;72(8):2089-99. doi: 10.1158/0008-5472.CAN-11-3019. Epub 2012 Apr 11.

36.

Immunotherapy: a useful strategy to help combat multidrug resistance.

Curiel TJ.

Drug Resist Updat. 2012 Feb-Apr;15(1-2):106-13. doi: 10.1016/j.drup.2012.03.003. Epub 2012 Apr 5. Review.

37.

Aged regulatory T cells protect from autoimmune inflammation despite reduced STAT3 activation and decreased constraint of IL-17 producing T cells.

Sun L, Hurez VJ, Thibodeaux SR, Kious MJ, Liu A, Lin P, Murthy K, Pandeswara S, Shin T, Curiel TJ.

Aging Cell. 2012 Jun;11(3):509-19. doi: 10.1111/j.1474-9726.2012.00812.x. Epub 2012 Mar 22.

38.

Aging-associated B7-DC+ B cells enhance anti-tumor immunity via Th1 and Th17 induction.

Tomihara K, Shin T, Hurez VJ, Yagita H, Pardoll DM, Zhang B, Curiel TJ, Shin T.

Aging Cell. 2012 Feb;11(1):128-38. doi: 10.1111/j.1474-9726.2011.00764.x. Epub 2011 Nov 28.

39.

Parasite mitogen-activated protein kinases as drug discovery targets to treat human protozoan pathogens.

Brumlik MJ, Pandeswara S, Ludwig SM, Murthy K, Curiel TJ.

J Signal Transduct. 2011;2011:971968. doi: 10.1155/2011/971968. Epub 2011 Feb 27.

40.

Immune therapy for ovarian cancer: promise and pitfalls.

Thibodeaux SR, Curiel TJ.

Int Rev Immunol. 2011 Apr-Jun;30(2-3):102-19. doi: 10.3109/08830185.2011.567361. Review.

PMID:
21557637
41.

CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice.

Wang L, Fan J, Thompson LF, Zhang Y, Shin T, Curiel TJ, Zhang B.

J Clin Invest. 2011 Jun;121(6):2371-82. doi: 10.1172/JCI45559. Epub 2011 May 2.

42.

Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis.

Chakravarty D, Roy SS, Babu CR, Dandamudi R, Curiel TJ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Vadlamudi RK.

Clin Cancer Res. 2011 Apr 15;17(8):2250-9. doi: 10.1158/1078-0432.CCR-10-2718. Epub 2011 Mar 18. Erratum in: Clin Cancer Res. 2013 Mar 1;19(5):1305.

43.

Human p38 mitogen-activated protein kinase inhibitor drugs inhibit Plasmodium falciparum replication.

Brumlik MJ, Nkhoma S, Kious MJ, Thompson GR 3rd, Patterson TF, Siekierka JJ, Anderson TJ, Curiel TJ.

Exp Parasitol. 2011 Jun;128(2):170-5. doi: 10.1016/j.exppara.2011.02.016. Epub 2011 Feb 19.

44.

Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer.

Rhodes LV, Short SP, Neel NF, Salvo VA, Zhu Y, Elliott S, Wei Y, Yu D, Sun M, Muir SE, Fonseca JP, Bratton MR, Segar C, Tilghman SL, Sobolik-Delmaire T, Horton LW, Zaja-Milatovic S, Collins-Burow BM, Wadsworth S, Beckman BS, Wood CE, Fuqua SA, Nephew KP, Dent P, Worthylake RA, Curiel TJ, Hung MC, Richmond A, Burow ME.

Cancer Res. 2011 Jan 15;71(2):603-13. doi: 10.1158/0008-5472.CAN-10-3185. Epub 2010 Dec 1. Erratum in: Cancer Res. 2011 May 1;71(9):3432.

45.

B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses.

Lin PY, Sun L, Thibodeaux SR, Ludwig SM, Vadlamudi RK, Hurez VJ, Bahar R, Kious MJ, Livi CB, Wall SR, Chen L, Zhang B, Shin T, Curiel TJ.

J Immunol. 2010 Sep 1;185(5):2747-53. doi: 10.4049/jimmunol.1000496. Epub 2010 Aug 4.

46.

Antigen-specific immunity and cross-priming by epithelial ovarian carcinoma-induced CD11b(+)Gr-1(+) cells.

Tomihara K, Guo M, Shin T, Sun X, Ludwig SM, Brumlik MJ, Zhang B, Curiel TJ, Shin T.

J Immunol. 2010 Jun 1;184(11):6151-60. doi: 10.4049/jimmunol.0903519. Epub 2010 Apr 28.

47.

CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression.

Jin D, Fan J, Wang L, Thompson LF, Liu A, Daniel BJ, Shin T, Curiel TJ, Zhang B.

Cancer Res. 2010 Mar 15;70(6):2245-55. doi: 10.1158/0008-5472.CAN-09-3109. Epub 2010 Feb 23.

48.

A simple method to detect Toxoplasma gondii-specific cytotoxic T cells in vivo.

Daniel BJ, Pandeswara S, Brumlik MJ, Liu A, Thibodeaux SR, Ludwig SM, Sun X, Curiel TJ.

J Immunol Methods. 2010 Apr 15;355(1-2):86-90. doi: 10.1016/j.jim.2010.01.013. Epub 2010 Feb 8.

49.

Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines.

Ruter J, Barnett BG, Kryczek I, Brumlik MJ, Daniel BJ, Coukos G, Zou W, Curiel TJ.

Front Biosci (Landmark Ed). 2009 Jan 1;14:1761-70. Review.

PMID:
19273160
50.

Regulatory T cells: a new frontier in cancer immunotherapy.

Barnett BG, Rüter J, Kryczek I, Brumlik MJ, Cheng PJ, Daniel BJ, Coukos G, Zou W, Curiel TJ.

Adv Exp Med Biol. 2008;622:255-60. doi: 10.1007/978-0-387-68969-2_20. Review. No abstract available.

PMID:
18546633

Supplemental Content

Loading ...
Support Center